EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.
December 01, 2021
Share
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. (OTCPK:IMUC) in a reverse merger transaction on December 1, 2021. Post-merger, ImmunoCellular's then-current equity holders will own approximately 3.5% and the former EOM equity holders will own approximately 96.5% percent of ImmunoCellular's common stock, calculated on a fully diluted basis. ImmunoCellular will be renamed EOM Pharmaceuticals Holdings, Inc. Pending the assignment of a new ticker symbol, EOM Pharmaceuticals' Common Stock will continue to be quoted on the OTC Markets under the ticker symbol "IMUC." EOM Pharmaceuticals Holdings, Inc. will be headquartered in Montvale, NJ. Effective with the merger, all existing officers and directors of EOM have assumed their same positions in the new company and all existing officers and directors of ImmunoCellular have resigned. The new senior leadership team at EOM Pharmaceuticals Holdings, Inc. includes Chief Executive Officer Irach Taraporewala.; EOM Founder, Board Chairman, and Chief Operating Officer Eli Goldberger; EOM Co-founder, Chief Scientific Officer and Medical Director Shalom Z. Hirschman; Wayne I. Danson, Chief Financial Officer and Treasurer; and Scientific Advisor and Chair of the Scientific Advisory Board, Frank L. Douglas. The transaction has been unanimously approved by the board of directors of both companies. Bridgeway Capital Partners and its affiliates served as exclusive financial advisor to EOM on the transaction.
EOM Pharmaceuticals, Inc. completed the acquisition of ImmunoCellular Therapeutics, Ltd. (OTCPK:IMUC) in a reverse merger transaction on December 1, 2021.
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their portfolio: EOM613 and EOM147. EOM613 is an investigational immunomodulator. EOM613 is a peptide-nucleic acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. EOM613 helps to suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells resulting in either further activation or suppression. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM147 affects multiple angiogenic growth factors such as VEGF, PdGF, and bFGF.